Semaglutide
STEP 4
Novo Nordisk · Phase 3 · Completed · Enrollment 902
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
- Semaglutide: week 20 -8.3%
- Placebo: week 20 6.5%
One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.